Low risk of attrition among adults on antiretroviral therapy in the Rwandan national program: a retrospective cohort analysis of 6, 12, and 18 month outcomes
We report levels and determinants of attrition in Rwanda, one of the few African countries with universal ART access.
Methods
We analyzed data abstracted from health facility records of a nationally representative sample of adults [≥18 years] who initiated ART 6, 12, and 18 months prior to data collection; and collected facility characteristics with a health facility assessment questionnaire. Weighted proportions and rates of attrition [loss to follow-up or death] were calculated, and patient- and health facility-level factors associated with attrition examined using Cox proportional hazard models.
Results
1678 adults initiated ART 6, 12 and 18 months prior to data collection, with 1508 person-years [PY] on ART. Attrition was 6.8% [95% confidence interval [CI] 6.0-7.8]: 2.9% [2.4-3.5] recorded deaths and 3.9% [3.4-4.5] lost to follow-up. Population attrition rate was 7.5/100PY [6.1-9.3]. Adjusted hazard ratio [aHR] for attrition was 4.2 [3.0-5.7] among adults enrolled from in-patient wards [vs 2.2 [1.6-3.0] from PMTCT, ref: VCT]. Compared to adults who initiated ART 18 months earlier, aHR for adults who initiated ART 12 and 6 months earlier was 1.8 [1.3-2.5] and 1.3 [0.9-1.9] respectively. Male aHR was 1.4 [1.0-1.8]. AHR of adults enrolled at urban health facilities was 1.4 [1.1-1.8, ref: rural health facilities]. AHR for adults with CD4+ ≥200 cells/μL vs <200 cells/μL was 0.8 [0.6-1.0]; and adults attending facilities with performance-based financing since 2004–2006 [vs. 2007–2008] had aHR 0.8 [0.6-0.9].
Conclusions
Attrition was low in the Rwandan national program. The above patient and facility correlates of attrition can be the focus of interventions to sustain high retention.
The online version of this article (doi:10.1186/1471-2458-14-889) contains supplementary material, which is available to authorized users.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the analysis: BE, HNB. Substantially contributed to protocol development and data collection: PB, HNB, BE, VM, AA, DN. Analyzed the data: AJ, HNB, BE. Wrote the paper: HNB, AJ. Critically revised the paper: BE, PB, VM, AA, DN. All authors reviewed and approved the final version.
Background
Millions of HIV-infected adults have initiated antiretroviral therapy [ART] in the past decade, but the overall impact of these programs can be compromised by patient attrition, including death and loss to follow-up [1‐8]. Rwanda is one of a handful of African countries to have achieved universal ART access, with at least 80% of the people eligible for ART receiving it [9, 10]. ART services in Rwanda were established in 2002, and by 2012, over 100,000 HIV-infected patients had initiated ART at more than 400 health facilities [11, 12]. High levels of retention on ART were reported for the first few years of the national program [13, 14]; indeed, in a nationally representative study conducted in 2004–2005, 92% and 86% of patients who initiated ART 6 and 12 months earlier, respectively, were alive and on ART at the health facility of ART initiation [13]. Over time, the national program expanded significantly, with over a five-fold increase in the number of facilities providing ART and the number of patients initiating ART [12]. As Rwanda, continues to build sustainable ART programs, it is important to continually assess whether these high levels of retention can be sustained with program scale-up and universal ART access. We use data from a nationally representative study of adults initiating ART to report on levels and correlates of attrition.
Methods
Study design and data collected
The data presented here were collected between September 2008 and April 2009 as part of a nationally-representative study of adherence among adults on ART. The full methods have been described elsewhere [15], but briefly multi-stage sampling was used to select 1,798 adults who had initiated ART approximately 6, 12 and 18 months prior to data collection across 20 HIV health facilities from the total of 9,693 adults receiving ART at 113 health facilities in Rwanda at the time of sampling (Figure 1). Data from patient medical charts and pharmacy records—including demographic and clinical characteristics, dates of ART initiation and health facility visits, and patient outcomes—were abstracted by trained study personnel using a structured tool. A health facility assessment questionnaire captured information on characteristics of each of health facility including the type and location of the health facility in which HIV services were located, availability of supportive services for ART patients e.g. home visits and timing of the introduction of performance based financing. In this setting, performance based financing was a supply-side intervention that provided health facilities a payment mechanism based on fees for services (conditional on quality) to motivate health workers to increase quality health outputs. Key HIV indicators (like number of patients tested for HIV, number of patients newly initiating ART) were rewarded with financial incentives and infrastructural support. We hypothesized those facilities that had performance based financing for longer would be motivated to ensure better health outcomes among patients, including retention.
Figure 1
Sampling and participant selection. *Data obtained from TRACNet, the national monitoring and evaluation system. **Data not found in clinic records at the time of data abstraction.
×
Anzeige
Inclusion criteria
During the study period the national adult ART initiation criteria in Rwanda were CD4 < 200 cells/μL or WHO stage IV, with stavudine and zidovudine as the main nucleoside reverse-transcriptase inhibitors used in first line ART regimens [16]. Patients sampled for the study described above were eligible for this analysis if they were 18 years or older, and had initiated first-line ART at one of the study facilities 6, 12, and 18 months [+/− 2 months] prior to data collection or transferred into one of the study facilities within 30 days of ART initiation. We aimed to determine the population estimate of attrition by conducting secondary analysis of an existing dataset, using the entire sample. Basing on Lowrance et al’s estimates of death and lost to follow-up, we determined that a dataset of 1798 would allow detection of attrition between 5% and 7% with >90% power and 5% precision. Of the 1798 adults originally sampled, 120 were excluded as they started ART outside of the above-specified timeframe [n = 24], were missing information on the date of ART initiation [n = 90], ART regimen [n = 1], and age [n = 1], or transferred to another health facility on the same day as starting ART [n = 4], resulting in a final analytic sample of 1678 adults (Figure 1).
Outcome
The outcome for this analysis was attrition, which included patients who were known to have died and those who were lost to follow-up [LTF]. Adults were considered LTF if they were not known to have died or transferred to another health facility and had not made a clinical or pharmacy visit in the 90 days before data abstraction. Adults were considered retained on ART if they picked up ART in the 90 days preceding data abstraction. Adults who were recorded as transferring out to another health facility were reported in a separate category, and not included in the retained or attrition outcomes.
Statistical methods
Statistical analysis was conducted using Stata software version 12.1 [StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP]. Survey procedures, including finite population correction, were used to adjust estimates for the complex survey design. We applied sampling weights that took into account the probability of a health facility being selected from the 113 health facilities providing ART at the time of sampling and the probability of a participant being selected from all adults who initiated ART at 6, 12 and 18 months previously, and thus results presented in this paper represent population-wide estimates of attrition. Descriptive statistics were computed for patient- and health facility-level characteristics. We calculated the proportion and rates per 100 person years [PY] of attrition for the entire population and by time on ART [i.e. 6, 12 and 18 months], and the 95% confidence interval around these estimates. Adults who transferred to another health facility were censored at the date of transfer.
Patient- and health facility-level factors associated with attrition were modeled using weighted data in bivariate and multivariable Cox proportional hazard models to calculate crude and adjusted hazard ratios and 95% confidence intervals. Variables included in the model were pre-selected according to hypothesised relevance and data availability, excluding variables that were collinear or lacked heterogeneity. We aggregated adults who had initiated ART 6, 12, and 18 months prior to data collection to increase statistical power, and controlled for time since ART initiation in the multivariable model.
Anzeige
Ethical considerations
The study protocol was approved by the Rwanda National Ethics Committee and the Institutional Review Board at Columbia University. This study was funded through the President’s Emergency Plan for AIDS Relief [PEPFAR] through the Centers for Disease Control and Prevention [CDC] and received Associate Director of Science [ADS] clearance. This analysis was based on data collected by abstraction from existing medical records; individual-level patient consent was waived by all approving ethical boards, and not sought.
Results
A total of 1678 adults were included in this analysis, 644 [37.4%], 578 [33.3%], and 456 [29.3%] who had initiated ART 6, 12 and 18 months prior to data collection, respectively. The total amount of follow-up time was 1508 person years, while the average follow-up time was 11.3 months. The weighted population was 8,373, 3123 [37.3%], 2762 [33.0%], and 2488 [29.7%] patients who had initiated ART 6, 12 and 18 months prior to data collection respectively, and represented 86.4% of the sampling frame population of 9,693.
Table 1 shows the characteristics of the population on ART. Median age of the population at ART initiation was 36 years [IQR 30–43] and 64.6% were female. Over two thirds [69.0%], were enrolled into the ART program from voluntary counseling and testing [VCT] services, while 14.6% enrolled from PMTCT services and 4.9% from in-patient wards. The majority [63.6%] were classified as WHO stage I or II at the time of ART initiation, with only 2.4% missing WHO stage data at ART initiation. CD4+ counts at ART initiation were available for 84.9% of the population. Among those with available data, median CD4+ count was 206 cells/μL [IQR 137–286], and 37.0% had CD4+ count less than 200cells/μL at the time of ART initiation. Of note, the median CD4 count at ART initiation among adults who started ART as in-patients was 74 cells/μL [IQR 34–194] vs 218 cells/μL [IQR 150–288] among patients enrolled from VCT and 256 cells/μL [IQR 177–313] among patients enrolled from PMTCT clinics. The majority of the population initiated stavudine [58.9%] and zidovudine [40.9%] in the first-line regimen, all combined with lamivudine and nevirapine [90.3%] or efavirenz [9.1%].
Table 1
Patient characteristics: overall distribution and by time on ART
Time on ART prior to data collection
Overall (all adults)
6 months on ART
12 months on ART
18 months on ART
p-value
n = 1,678
n = 644
n = 578
n = 456
N
Weighted %
N
Weighted %
N
Weighted %
N
Weighted %
Patient-level characteristics
Age groups
18-25 years
200
10.7
61
8.4
76
12.1
63
12.1
26-35 years
619
35.5
229
33.8
210
34.8
180
38.4
36-45 years
562
33.8
227
36.4
185
32.4
150
32.2
46+ years
297
20.0
127
21.5
107
20.7
63
17.3
0.010
Gender
Female
1079
64.6
414
64.2
380
65.9
285
63.8
Male
229
35.4
229
35.8
195
34.1
170
36.2
0.361
Source of referral to ART clinic
VCTa
1157
69.0
460
70.6
400
68.4
297
67.7
PMTCTb
282
14.6
102
14.6
92
14.1
88
15.2
In-patient ward
70
4.9
21
4.0
20
4.1
29
6.9
Otherc
169
11.5
61
10.8
66
13.4
42
10.2
0.172
WHO stage at ART initiationd
Stage I and II
1019
63.6
448
71.7
320
60.5
251
56.8
Stage III
559
32.7
163
25.5
218
35.4
178
39.0
Stage IV
65
3.7
20
2.8
26
4.1
19
4.3
<.001
CD4+ count (cells/μL) at ART initiation
0 – 199
689
37.1
180
25.7
273
42.1
236
46.0
200 +
753
47.8
357
58.1
236
45.3
160
37.5
Missing
236
15.1
107
16.3
69
12.6
60
16.5
<.001
Initial ART regimen containing…
Stavudine
942
58.9
184
34.1
387
65.3
371
83.3
<.001
Zidovudine
731
40.9
459
65.8
188
34.1
84
16.6
Tenofovir
5
0.2
1
0.1
3
0.6
1
0.1
Characteristics of clinic attended
Location
Rural
599
50.0
215
47.6
221
53.6
163
49.1
Urban
1079
50.0
429
52.4
357
46.4
293
50.9
0.781
Facility level
Health center
914
64.2
349
63.8
326
66
239
62.5
Hospital
764
35.8
295
36.2
252
34
217
37.5
0.928
Facility ownership
Faith-based
537
25.3
212
23.0
183
25.6
142
27.7
Public
1141
74.7
432
77.0
395
74.4
314
72.3
0.123
Start of performance based financing
2004-2006
919
55.2
363
55.7
332
59.0
224
50.1
2007-2008
759
44.9
281
44.3
246
41.0
232
49.9
0.628
Home visits support for PLWHAe
887
50.9
333
49.6
304
52.6
250
50.6
0.942
aVCT = Voluntary Counseling and Testing services; bPMTCT = Prevention of Mother-to-Child HIV Transmission.
cIncludes Tuberculosis clinics [n = 17], outpatient services [n = 45] and other modes of admission [n = 107].
dAdults missing data on WHO stage at ART initiation [n = 35, 2.1%].
ePLWHA = Persons Living with HIV/AIDS.
Half the population attended health facilities located in rural areas [50.0%], and the majority attended health centers [64.2%, vs 35.8% at hospitals]; and public government facilities [74.7%, vs 25.3% at faith based health facilities]. All health facilities had performance based financing Nearly half [44.9%] of the population attended health facilities where performance based financing had been introduced more recently [2007–2008 vs. 2004–2006] and half attended health facilities where home visit support services for patients who miss health facility visits were available [50.9%].
When comparing the population by time of ART initiation, the population who initiated ART 6 and 12 months prior to data collection had a higher proportion of older adults [36 years and older], adults with WHO Stage I and II at ART initiation, and adults with CD4+ count above 200 cells/μL at ART initiation, than the population who initiated ART 18 months prior to data collection. Stavudine use in the initial ART regimen declined from 83.3% to 65.3% and 34.1% for adults who had initiated ART 18, 12 and 6 months previously, while zidovudine use increased from 16.6% to 34.1% and to 65.8% respectively.
Of the population that initiated ART, 5.5% transferred out to other health facilities. Of the remaining population, attrition was observed among 6.8%, with 2.9% documented to have died and 3.9% lost to follow-up [Table 2]. Attrition among adults who had initiated ART 6, 12 and 18 previously was 3.5%, 8.8% and 8.8% respectively. The population attrition rate was 7.5/100 PY, with deaths accounting for 3.2/100 PY and loss to follow-up 4.3/100PY [Table 2]. Attrition rates among adults who had initiated ART 6, 12 and 18 previously were 6.9/100 PY, 9.1/100 PY and 6.4/100 PY respectively.
Table 2
Proportion and rate of attrition and transfers per 100 person years: overall and by time on ART
Time on ART prior to data collection
Overall (all adults)
6 months on ART
12 months on ART
18 months on ART
1509 person years
330 person years
559 person years
619 person years
1678 adults
644 adults
578 adults
456 adults
Proportions:
n
Weighted %
95% CI
n
Weighted %
95% CI
n
Weighted %
95% CI
n
Weighted %
95% CI
Attrition
135
6.8
[6.0 – 7.8]
25
3.5
[2.7 – 4.5]
58
8.8
[7.1 – 10.9]
52
8.8
[7.9 – 11.4]
Recorded death
48
2.9
[2.4 – 3.5]
13
1.6
[1.1 – 2.3]
16
2.9
[2.0– 4.1]
19
4.6
[3.5 – 6.0]
Lost to follow-up
87
3.9
[3.4 – 4.5]
12
1.9
[1.3 – 2.7]
42
5.9
[5.0 – 7.0]
33
4.2
[3.2 – 5.6]
Transfer out
99
5.5
[4.5 – 6.8]
34
6.1
[4.5 – 8.2]
26
3.6
[2.5 – 5.3]
39
6.9
[4.8 – 9.8]
Retained on ART
1444
87.7
[86.0 – 89.2]
585
90.4
[88.4 – 92.2]
494
87.6
[84.7 – 90.0]
365
84.3
[80.4 – 87.5]
Rates:
No.
Weighted rate
95% CI
No.
Weighted rate
95% CI
No.
Weighted rate
95% CI
No.
Weighted rate
95% CI
Attrition
135
7.5
[6.1 – 9.3]
25
6.9
[4.3 – 11.9]
58
9.1
[6.6 – 12.7]
52
6.4
[4.6 – 9.2]
Recorded death
48
3.2
[2.3 – 4.5]
13
3.2
[1.7 – 6.9]
16
2.9
[1.6 – 5.6]
19
3.3
[2.0 – 5.9]
Lost to follow-up
87
4.3
[3.3 – 5.6]
12
3.7
[1.8 – 8.8]
42
6.1
[4.2 – 9.2]
33
3.1
[2.0 – 4.9]
Transfer out
99
6.0
[4.7 – 7.8]
34
12.1
[7.9 – 19.4]
26
3.7
[2.4 – 6.3]
39
5.0
[3.4 – 7.5]
Retained on ART
1444
95.7
[92.8 – 98.7]
585
179.5
[174.5 – 184.6]
494
90.3
[88.1 – 92.6]
365
61.1
[59.5 – 62.7]
Note: Some percentages may not add to 100% due to rounding.
Table 3 displays patient- and health facility-level characteristics associated with attrition in the bivariate and multi-variable analyses adjusting for various demographic, clinical and site characteristics. The adjusted hazard ratio [aHR] for attrition was highest for adults enrolled from in-patient wards: aHR 4.2 [95% CI: 3.0-5.7]; and PMTCT services: aHR 2.2 [95% CI: 1.6-3.0], compared to those enrolled from VCT services. Compared to adults who initiated ART 18 months earlier, adults who initiated ART 12 months earlier had higher hazard of attrition: aHR 1.8 [95% CI: 1.3-2.5]; but no significant difference was observed with adults who had initiated ART in the previous 6 months: aHR 1.3 [95% CI: 0.9 – 1.9]. A higher hazard of attrition was also observed among men: aHR 1.4 [95% CI: 1.0-1.8] than women; and adults attending urban health facilities: aHR 1.4 [95% CI: 1.1-1.8] compared to those attending rural facilities.
Table 3
Crude and adjusted Cox proportional models for the hazard of attrition (death or loss to follow-up)
Bivariate analysis
Multi-variable model n = 1,678
Attrition N
HR of attrition
95% CI
p-value
aHR of attrition
95% CI
p-value
Time on ART prior to data collection
18 months on ART
52
Ref
Ref
6 months on ART
25
1.1
[0.8 – 1.7]
0.517
1.3
[0.9 - 1.9]
0.190
12 months on ART
58
1.7
[1.2 - 2.4]
0.003
1.8
[1.3 - 2.5]
0.000
Age
18-25 years
27
Ref
Ref
26-35 years
48
0.8
[0.5 - 1.2]
0.195
0.8
[0.5 - 1.3]
0.395
36-45 years
44
0.9
[0.6 - 1.2]
0.318
1.0
[0.7 - 1.4]
0.864
46+ years
16
0.6
[0.4 - 0.9]
0.014
0.8
[0.5 - 1.3]
0.379
Gender
Females
48
Ref
Ref
Males
87
1.3
[1.0 - 1.6]
0.066
1.4
[1.0 - 1.8]
0.027
Source of referral to ART clinic
Voluntary Counseling and Testing
70
Ref
Ref
PMTCT services
35
2.1
[1.6 - 2.7]
0.000
2.2
[1.6 - 3.0]
0.000
In-patient ward
15
4.1
[3.0 - 5.6]
0.000
4.2
[3.0 - 5.7]
0.000
Other
15
1.6
[1.2 - 2.2]
0.001
1.5
[1.1 - 2.0]
0.004
CD4+ count at ART initiation (cells/μL)
0 – 199
69
Ref
Ref
200+
45
0.7
[0.5 - 0.9]
0.005
0.8
[0.6 - 1.0]
0.031
Missing
21
1.0
[0.7 - 1.3]
0.763
1.0
[0.8 - 1.3]
0.811
Initial ART regimen
Stavudine containing
80
Ref
Ref
Zidovudine containing
54
1.1
[0.9 - 1.3]
0.423
1.0
[0.8 - 1.2]
0.944
Tenofovir containing
1
1.6
[0.7 - 3.6]
0.240
1.7
[0.8 - 3.9]
0.165
Location
Rural
32
Ref
Ref
Urban
103
1.5
[1.1 - 2.0]
0.005
1.4
[1.1 - 1.8]
0.013
Facility level*
Hospitals
52
Ref
Ref
Health centers
83
0.9
[0.7 - 1.2]
0.483
0.8
[0.6 - 1.1]
0.226
Start of performance based financing
2007-2008
85
Ref
Ref
2004-2006
50
0.9
[0.6 - 1.2]
0.239
0.8
[0.6 - 0.9]
0.016
Home support visits for PLWHA available
No
60
Ref
Ref
Yes
75
1.2
[0.9 - 1.6]
0.415
1.2
[1.0 - 1.6]
0.097
*Facility ownership variable (public vs faith based) excluded from the model due to collinearity with facility level variable.
The hazard of attrition was lower among adults whose CD4+ count at ART initiation was 200 cells/μL or greater, aHR 0.8 [95% CI: 0.6-1.0], compared to those who initiated ART with CD4+ counts below 200 cells/μL. Lower attrition hazard was also observed among adults who attended health facilities that had longer-standing performance-based financing [since 2004–2006], aHR 0.8 [95% CI: 0.6-0.9], compared to patients attending health facilities where performance based financing had began more recently [2007–2008]. Age, initial ART regimen, level of health facility and availability of home visit services were not significantly associated with attrition in adjusted analyses.
Anzeige
Discussion
We assessed levels of attrition 6, 12 and 18 months following ART initiation among a nationally representative sample of adults receiving HIV services in Rwanda. We estimated overall population attrition to be 6.8% and the attrition rate as 7.5/100 PY. Lowrance et al., who explored this question in the early phase of the Rwanda ART program [2004–2005], reported attrition of 6.7% of patients at 6 months and 9.5% at 12 months on ART [13]. We found much lower attrition at 6 months, 3.5%, and approximately the same attrition at 12 months, 8.8%, in 2007–2008, suggesting a significant reduction in attrition at the 6 months following ART initiation. Our results tally with more recent findings using a significantly larger sample in two regions of Rwanda [17]. This is an important finding because the risk of attrition tends to be highest immediately after ART initiation, and is usually due to high mortality within this time period [18‐20]. These findings may reflect the benefits of initiating ART earlier in HIV disease, as the median CD4+ count at ART initiation in our sample was 65 cells/μL, higher than that observed by Lowrance et al.
While Lowrance et al. observed that death and LTF contributed equally to attrition in the early phase of ART scale-up in Rwanda, our data indicate that LTF increasingly accounts for the majority of attrition. This may reflect deteriorating ascertainment and documentation of deaths as the ART program expands, and an increase in undocumented transfers as ART services are decentralized [20‐22]. Stronger linkages and feedback between communities and health facilities [to report deaths] and between health facilities [to report transfers] could result in more accurate estimations of true loss to follow-up, mortality, and transfers and thus more complete assessment of the ART program impact.
While the level of attrition observed in our sample was in-line with other findings from Rwanda [13, 14, 23, 17], it is substantially lower than that observed in other programs within the East African region, which report attrition in the range of 18% to 40% 12 months after ART initiation [24‐28]. Multiple factors may be contributing to the low attrition in ART programs in Rwanda. First, the median CD4+ count at ART initiation in our population was significantly higher than has been observed in other countries [18, 25, 29, 30], and could account for this association. Our results also showed that CD4+ counts >200/μL were associated with a 20% reduction in attrition. Notably, patients whose CD4+ counts at ART initiation were missing had similar hazard of attrition to the patients with the lowest CD4+ counts. This finding suggests that patients whose CD4+ counts are not assessed and recorded at ART initiation may be as vulnerable to attrition as the sickest patients. Secondly, adults in the Rwanda ART program tend to have high adherence to ART [31, 32] which in turn can reduce mortality, and thus attrition. This is further evidenced by adherence and viral load assessments conducted on a subset of participants in this analysis which revealed that overall [combining adults on ART 6, 12 and 18 months], 94% and 78% took 100% of their medication in the 3 and 30 days preceding the interview, and 83% had viral load under 40 copies/mL at the time of interview [15].
The most significant factor associated with increased hazard of attrition in our study was starting ART while admitted within an in-patient ward. This finding has been observed by others [33], and is likely due to high mortality in this severely ill group and LTF due to undocumented deaths [20, 34]. Indeed, the median CD4 count at ART initiation among in-patients was about a third of observed among other study participants. Recent recommendations by WHO and the Rwanda Ministry of Health [35‐37], which endorse ART initiation at higher CD4 counts [350 cells/μ/L and more recently 500 cells/μ/L], could result in adults initiating ART earlier in HIV disease, and thus lower attrition. Enrolling from PMTCT services was also associated with high attrition. This has been observed in a number of African programs [38, 39], and is a challenge worth addressing as countries begin to implement for life-long ART for all pregnant and breastfeeding women. The finding that men had higher attrition than women is not uncommon in African HIV treatment programs [40‐44]; this is a high risk group that requires targeted interventions to minimize attrition.
Anzeige
Adults who attended health facilities with a longer duration of performance based financing had a lower hazard attrition in our analysis. Although our analysis lacked data to comparatively examine attrition at facilitates without performance based financing, implementation of performance based financing is perceived as a strong motivator for provision of better health care services [45‐47], and may have contributed to improvements in patient outcomes at these health facilities clinics. It is possible that sites that initiated performance based financing earlier had other unmeasured characteristics that influenced attrition outcomes, and further research should examine the specific impact of this strategy on lowering attrition in African ART programs.
Our study did not find a correlation between home visits and attrition, a finding in line with results of a multi-country ecological study examining the impact of site-level factors on attrition [48]. Whereas it has been observed that home-visits can be associated with better retention [49], it is likely that in our setting of high retention, the impact of home visits was minimal, particularly if targeted to patients with high risk of attrition that may have insurmountable barriers to returning to care.
Our study had a number of strengths. We had a large sample of adults drawn from a nationally representative sample of adults on ART, and there was representation from different types of health facilities in various settings. The study was conducted in one of the first few African countries to achieve universal ART access. In multivariate analyses, we explored associations between both patient- and health facility- level factors and attrition. A limitation to note, however, is that the study lacked sufficient power to examine factors associated with death and LTF in separate models or present results stratified by time on ART. Despite this, the results effectively demonstrate the low attrition rates and some key factors associated with the risk of attrition for the overall population.
Conclusion
Our results suggest sustained low attrition in the Rwanda national ART program in the context of significant expansion in the number of clinics providing HIV care and treatment services and the number of patients on ART. Loss to follow-up was the more significant contributor to attrition suggesting that better ascertainment and documentation of deaths and patient transfers may be necessary. In this context of universal ART access, specific groups remain at risk of high attrition [including in-patients, men, PMTCT clients and adults attending urban facilities] and require targeted interventions to further reduce attrition. Performance-based financing could be a useful tool in minimizing attrition in this context.
Anzeige
Acknowledgements
We thank the participants and staff at the facilities included in the study for their participation; study co-investigators, collaborators and the field team. The work in this publication was supported by the United States President’s Emergency Plan for AIDS Relief [PEPFAR] through the United States Centers for Disease Control and Prevention [CDC] under the terms of Cooperative Agreement Number U62/CCU222407 in partnership with the Global Fund to Fight AIDS, Tuberculosis and Malaria. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of PEPFAR, CDC or Global Fund.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the analysis: BE, HNB. Substantially contributed to protocol development and data collection: PB, HNB, BE, VM, AA, DN. Analyzed the data: AJ, HNB, BE. Wrote the paper: HNB, AJ. Critically revised the paper: BE, PB, VM, AA, DN. All authors reviewed and approved the final version.
Low risk of attrition among adults on antiretroviral therapy in the Rwandan national program: a retrospective cohort analysis of 6, 12, and 18 month outcomes
